As of November 19 at 3:24 PM EST. Market Open.
Breakdown
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
Total Revenue
98.5220
98.5220
43.0880
16.0480
--
Cost of Revenue
26.4350
26.4350
1.8020
164.4270
--
Gross Profit
72.0870
72.0870
41.2860
-148.3790
--
Operating Expense
449.7200
449.7200
873.4590
1,668.2630
1,567.2770
Operating Income
-377.6330
-377.6330
-832.1730
-1,816.6420
-1,567.2770
Net Non Operating Interest Income Expense
29.2900
29.2900
28.9040
-68.9380
-65.2800
Other Income Expense
8.4950
8.4950
-978.2750
-53.7410
6.0000
Pretax Income
-339.8480
-339.8480
-1,781.5440
-1,939.3210
-1,626.5570
Net Income Common Stockholders
-339.8480
-339.8480
-1,781.5440
-1,939.3210
-1,626.5570
Diluted NI Available to Com Stockholders
-339.8480
-339.8480
-1,781.5440
-1,939.3210
-1,626.5570
Basic EPS
-0.08
--
-0.40
-0.50
-0.40
Diluted EPS
-0.08
--
-0.40
-0.50
-0.40
Basic Average Shares
4,262.8380
--
4,110.0300
3,909.7070
4,100.0000
Diluted Average Shares
4,262.8380
--
4,110.0300
3,909.7070
4,100.0000
Rent Expense Supplemental
--
--
17.1880
31.4810
92.1180
Total Expenses
476.1550
476.1550
875.2610
1,832.6900
1,567.2770
Net Income from Continuing & Discontinued Operation
-339.8480
-339.8480
-1,781.5440
-1,939.3210
-1,626.5570
Normalized Income
-348.3430
-348.3430
-803.2690
-1,885.5800
-1,632.5570
Interest Income
29.2900
29.2900
65.0400
6.8360
3.0180
Interest Expense
--
--
36.1360
75.7740
68.2980
Net Interest Income
29.2900
29.2900
28.9040
-68.9380
-65.2800
EBIT
-339.8480
-339.8480
-1,745.4080
-1,863.5470
-1,558.2590
EBITDA
-319.4780
-319.4780
-1,679.3150
-1,724.0130
-1,465.4250
Reconciled Cost of Revenue
26.4350
26.4350
1.8020
164.4270
--
Reconciled Depreciation
20.3700
20.3700
66.0930
139.5340
92.8340
Net Income from Continuing Operation Net Minority Interest
-339.8480
-339.8480
-1,781.5440
-1,939.3210
-1,626.5570
Total Unusual Items Excluding Goodwill
8.4950
8.4950
-978.2750
-53.7410
6.0000
Total Unusual Items
8.4950
8.4950
-978.2750
-53.7410
6.0000
Normalized EBITDA
-327.9730
-327.9730
-701.0400
-1,670.2720
-1,471.4250
6/30/2021 - 11/16/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
MYND.CN MYND Life Sciences Inc.
0.0550
-26.67%
TELI.CN Telescope Innovations Corp.
0.3500
0.00%
IOT.V Innovotech Inc.
0.1700
-8.11%
MBX.TO Microbix Biosystems Inc.
0.3100
0.00%
MSCL.TO Satellos Bioscience Inc.
0.7400
-1.33%
DRUG.CN Bright Minds Biosciences Inc.
56.31
+6.79%
MDMA.CN Pharmala Biotech Holdings Inc.
0.3050
-4.69%
SVA.TO Sernova Corp.
0.2300
+4.55%
CYBN.NE Cybin Inc.
15.10
+2.37%
SLS SELLAS Life Sciences Group, Inc.
1.1800
+0.85%